Sanofi
This content has been provided by Sanofi Regeneron. The content is not influenced or endorsed by the European Respiratory Society
Dr Miguel Lanz discusses the role of FeNO (fractional exhaled nitric oxide) as a biomarker for type 2 inflammation in asthma and indicating how higher FeNO levels are linked to increased exacerbation rates and more rapid lung function decline.